An ataxia telangiectasia model: Inefficient cell differentiation and possible reversal by serine protease inhibitors, tumor necrosis factor inhibitors, dexamethasone, and glutathione enhancers

Medical Hypotheses

Volumn 51, Issue 1, 1998, Pages 53-57

  Knittweis, J ^a  

^a Research Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; DEXAMETHASONE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; SERINE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ATAXIA TELANGIECTASIA; CELL DIFFERENTIATION; CEREBELLAR ATAXIA; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INSULIN SENSITIVITY; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; TRANSGENIC MOUSE;

ATAXIA; ATAXIA TELANGIECTASIA; MUS MUSCULUS;

EID: 0031819766     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90254-7     Document Type: Article

References (88)

1. Shull M M, Ormsby L. Targeted disruption of the mouse transforming growth factor beta gene results in multifocal inflammatory disease. Nature 1992; 359: 693-697.
2. Saxon A, Stevens R H, Golde D W. Helper and suppressor t-lymphocyte leukemia in ataxia telangiectasia. N Engl J Med 1979; 300: 700-704.
3. Lindner D P, Poberii I A, Stetsenko O N. Refringence phenomenon as a sign of the degree of differentiation of immunocompetent cells. Arkh Patol 1976; 38: 81-83.
4. Zadik Z, Levin S, Prager-Lewin R, Laron Z. Gonadal dysfunction in patients with ataxia telangiectasia. Acta Paediatr Scand 1978; 67: 477-479.
5. Power S C, Cereghini S, Rollier A, Gannon F. Isolation and functional analysis of the promoter of the bovine serum albumin gene. Biochem Biophys Res Commun 1994; 203: 1447-1456.
6. Ng K H, Maigne J, Fougere-Deschatrette C, Poupon M F. Reversion and cell hybridization of a dedifferentiated rat hepatoma cell: dissociation of mechanisms establishing the hepatic traits. Exp Cell Res 1993; 207: 48-56.
7. Valet J P, Marceau N, Deschenes J. Restricted specialization of differentiating hepatocytes in terms of albumin and alpha-fetoprotein production. Cell Biol Int Rep 1981; 5: 307-314.'
8. Venetianer A, Bosze Z. Expression of differentiated functions in dexamethasone-resistant hepatoma cells. Differentiation 1983; 25: 70-78.
9. Ohama E, Ikuta F. Ataxia telangiectasia: immunocytochemical demonstration of alpha-fetoprotein and hepatitis B surface antigen in the liver. Acta Neuropathol 1982; 56: 13-16.
10. Ayache R, Najjar M F, Obeid H, Pousse H. Ataxia telangiectasia: clinical and biological study in 17 cases. Ann Biol Clin 1994; 52: 117-120.
11. Schwartzman J S, Sole D, Naspitz C K. Ataxia telangiectasia: a clinical and laboratory review study of 14 cases. Allergol Immunopathol 1990; 18: 105-111.
12. Ishiguro T, Taketa K, Gatti R A. Tissue of origin of elevated alpha-fetoprotein in ataxia telangiectasia. Dis Markers 1986; 4: 293-297.
13. Beatty D W, Arens L J, Nelson M M. Ataxia telangiectasia: X, 14 translocation, progressive deterioration of lymphocyte numbers and function, and abnormal in vitro immunoglobulin production. S African Med J 1986; 69: 115-118.
14. Vinters H V, Gatti R A, Rakic P. Sequence of cellular events in cerebellar ontogeny relevant to expression of neuronal abnormalities in ataxia telangiectasia. Kro Found Ser 1985; 19: 233-255.
15. Stephens L, Smrcka A, Cooke FT, Jackson TR, Sternweis P C, Hawkins P T. A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell 1994; 77: 83-93.
16. Kotani K, Carozzi A J, Sakaue H, Hara K, Robinson L J, Clark S F. Requirement for phosphoinositide 3-kinase in insulin-stimulated GLUT 4 translocation in 3T3-L1 adipocytes. Biochem Biophys Res Commun 1995; 209: 343-348.
17. Stephens L, Cooke F T, Walters R et al. Characterization of a phosphatidylinositol-specific phosphoinositide 3-kinase from mammalian cells. Curr Biol 1994; 4: 203-214.
18. Wennstrom S, Hawkins P, Cooke F et al. Activation of phosphoinositide 3-kinase is required for PDGF-stimulated membrane ruffling. Curr Biol 1994; 4: 385-393.
19. Tomiyama K, Nakata H, Sasa H, Arimura S, Nishior E, Watanabe Y. Wortmannin, a specific phosphatidylinositol 3-kinase inhibitor, inhibits adipocytic differentiation of 3T3-L1 cells. Biochem Biophys Res Commun 1995; 212: 263-269.
20. Uehara T, Tokumitsu Y, Nomura Y. Wortmannin inhibits insulin-induced Ras and mitogen-activated protein kinase activation related to adipocyte differentiation in 3T3-L1 fibroblasts. Biochem Biophys Res Commun 1995; 210: 574-580.
21. Cavallaro T, Martone R L, Stylianopolou F, Herbert J. Differential expression of the insulin-like growth factor II and transthyretin genes in the developing rat choroid plexus. J Neuropathol Exp Neurol 1993; 52: 153-162.
22. Masters B A Werner H, Roberts C T Jr, Leroith D, Raizada M K. Insulin-like growth factor I receptors and IGF-I action in oligodendrocytes from rat brains. Regul Pept 1991; 33: 117-131.
23. Ma Z Q, Santagati S, Patrone C, Pollio G, Vegetoi E, Maggi A. Insulin-like growth factors activate estrogen receptor to control the growth and differentiation of the human neuroblastoma cell line SK-ER3. Mol Endocrinol 1994; 8: 910-918.
24. Lavenius E, Parrow V, Nanberg E, Pahlman S. Basic FGF and IGF-I promote differentiation of human SH-SY5Y neuroblastoma cells in culture. Growth Factors 1994; 10: 29-39.
25. Wabitsch M, Hauner H, Heinze E, Teller W M. The role of growth hormone/insulin-like growth factors in adipocyte differentiation. Metabolism 1995; 44: 45-49.
26. Rosenthal S M, Cheng Z Q. Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc Natl Acad Sci USA 1995; 92: 10307-10311.
27. Quinn L S, Steinmetz B, Maas A, Ong L, Kaleko M. Type-1 insulin-like growth factor receptor overexpression produces dual effects on myoblasts proliferation and differentiation. J Cell Physiol 1994; 159: 387-398.
28. Liu X J, Sorisky A, Zhu L, Pawson T. Molecular cloning of an amphibian insulin receptor substrate 1-like cDNA and involvement of phosphatidylinositol 3-kinase in insulin-induced Xenopus oocyte maturation. Mol Cell Biol 1995; 15: 3563-3570.
29. Aizenman Y, de Vellis J. Synergistic action of thyroid hormone, insulin and hydrocortisone on astrocyte differentiation. Brain Res 1987; 414: 301-308.
30. Aizenman Y, de Vellis J. Brain neurons develop in a serum and glial free environment: effects of transferrin, insulin, insulin-like growth factor-I and thyroid hormone on neuronal survival, growth, and differentiation. Brain Res 1987; 406: 32-42.
31. Hernandez-Sanchez C, Lopez-Carranaza A, Alarcon C, de La Rosa E J, de Pablo F. Autocrine/paracrine role of insulin-related growth factors in neurogenesis: local expression and effects on cell proliferation and differentiation in retina. Proc Natl Acad Sci USA 1995; 92: 9834-9838.
32. Saad M J, Folli F, Araki E, Hasimoto N, Csermely P, Kahn C R. Regulation of insulin receptor, insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-F442A adipocytes: effects of differentiation, insulin, and dexamethasone. Mol Endocrinol 1994; 8: 545-557.
33. Shiloh Y, Tabor E, Becker Y. Colony-forming ability of ataxia telangiectasia skin fibroblasts is an indicator of their early senescence and increased demand for growth factors. Exp Cell Res 1982; 140: 191-199.
34. Becker Y, Shaham M, Tabor E, Shiloh Y. Ataxia telangiectasia - a human autosomal recessive disorder predisposing to cancer. In: Giraldo G, Beth E, eds. The Role of Viruses in Human Cancer, Vol. II. New York: Elsevier Science, 1984: 397-496.
35. Bar R S, Levis W R, Rechter M M. Extreme insulin resistance in ataxia telangiectasia: defect in affinity of insulin receptors. N Engl J Med 1978; 298: 1164-1171.
36. Blevins L S Jr, Gebhart S S. Insulin-resistant diabetes mellitus in a black woman with ataxia telangiectasia. South Med J 1996; 89: 619-621.
37. Schalch D S, McFarlin D E, Barlow M H. An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med 1970; 282: 1396-1402.
38. de Graaf A S, de Jong G, Kleijer W J. An early-onset recessive cerebellar disorder with distal amyotrophy and, in two patients, gross myoclonia: a probable ataxia telangiectasia variant. Clin Neurol Neurosurg 1995; 97: 1-7.
39. Moustacchi E. Possible interrelations between mutagenic responses, cytokine production, and cancer predisposition in genetic diseases with high susceptibility to genotoxic agents. In: Proceedings of the 85th annual meeting of the American Association for Cancer Research, San Francisco, California, 1994.
40. Siddoo-Atwal C, Haas A L, Rosin M P. Elevation of Interferon-beta proteins in ataxia telangiectasia cells. Cancer Res 1996; 56: 443-447.
41. Jung M, Chang Y, Lee S, Dritschilo A. Correction of radiation sensitivity in ataxia telangiectasia cells by a truncated 1k B-alpha. Science 1995; 268: 1619-1621.
42. Sun S, Elwood J, Greene W C. Both amino- and carboxyl-terminal sequences within I kappa B alpha regulate its inducible degradation. Mol Cell Biol 1996; 16: 1058-1065.
43. Chen C C, Rosenbloom C L, Anderson D C, Manning A M. Selective inhibition of E-selectin, vascular cell adhesion molecule-I, and intercellular adhesion molecule-1 expression by inhibitors of I kappa B alpha phosphorylation. J Immunol 1995; 155: 3538-3545.
44. Brockman J A, Scherer D C, McKinsey T A et al. Coupling of a signal response domain in I-kappa B alpha to multiple pathways for NP-kappa B activation. Mol Cell Biol 1995; 15: 2809-2818.
45. Machleidt T, Wiegmann K, Henkel T, Schutze S, Baeuerle P, Kronke M. J Biol Chem 1994; 269: 13760-13765.
46. Kanno T, Brown K, Siebenlist U. Evidence in support of a role for human T-cell leukemia virus type I tax in activating NF-kappa B via stimulation of signaling pathways. J Biol Chem 1995; 270: 11745-11748.
47. Baldi L, Brown K et al. Critical role for lysines 21 and 22 in signal-induced ubiquitin-mediated proteolysis of I-kappa B alpha. J Biol Chem 1996; 271: 376-379.
48. Di Donato J A, Mercurio F et al. Phosphorylation of I-kappa B alpha precedes but is not sufficient for its dissociation from NF kappa B. Mol Cell Bioll 1995; 15: 1302-1311.
49. Chen Z, Hagler J et al. Signal-induced site specific phosphorylation targets I-kappa B alpha to the ubiquitin proteasome pathway. Genes Dev 1995; 9: 1586-1597.
50. Brown K, Gerstberger S et al. Control of I-kappa B alpha proteolysis by site-specific, signal-induced phosphorylation. Science 1995; 267: 1485-1488.
51. Li C C, Dai M M et al. Inactivation of NF-kappa B inhibitor I-kappa B alpha: ubiquitin-dependent proteolysis and its degradation product. Biochem Biophys Res Commun 1995; 215: 292-301.
52. Whiteside S T, Ernst M K et al. N- and C-terminal sequences control degradation of MAD3/I-kappa B alpha in response to inducers of NP-kappa B activity. Mol Cell Biol 1995; 15: 5539-5545.
53. Prasad A V, Mohan N et al. Activation of nuclear factor kappa B in human lymphoblastoid cells by low dose ionizing radiation. Radiation Res 1994; 138: 367-372.
54. Brach M A, Hass R et al. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest 1991; 88: 691-695.
55. Valerie K, Laster W S et al. Ionizing radiation activates nuclear factor kappa B but fails to produce and increase in HIV virus gene expression in stably transfected human cells. Biochemistry 1995; 34: 15768-15776.
56. Boothman D A, Sahijdak W S et al. Transcription factor activation following ionizing radiation [Meeting abstract]. In: Proc Ann Meet Am Assoc Cancer Res 1994; 35: A3804.
57. Eissner G, Kohlhuber F et al. Critical involvement of transmembrane tumor necrosis factor alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood 1995; 86: 4184-4193.
58. Chen M, Quintans J et al. Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide. Cancer Res 1995; 55: 991-994.
59. Hallahan D E, Virudachalam S et al. Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing radiation. Cancer Res 1991; 51: 4565-4569.
60. Vara E, Arias-Diaz J et al. Cytokine-induced inhibition of lipid synthesis and hormone secretion by isolated human islets. Pancreas 1994; 9: 316-323.
61. Soldevila G, Buscema M et al. Cytotoxic effect of IFN gamma plus TNF alpha on human islet cells. J Autoimmune 1991; 4: 291-306.
62. Rabinovitch A, Sumoski W et al. Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. J Clin Endocrinol Metabol 1990; 71: 152-156.
63. Skowron G, Barditch-Crovo P et al. A phase I trial of oral procysteine in early HIV infection. Int Conf AIDS 1993; 9: 498 Abstract# PO-B29-2177.
64. Lederman M M, Georges D et al. Procysteine inhibits HIV-1 expression but not interleukin 2 secretion. Int Conf AIDS 1993; 9: 248 Abstract# PO-A28-0681.
65. Chen P, Schwartz D. Procysteine inhibits TNF-alpha induced HIV production in U1 cells. Int Conf AIDS 1993; 9: 176 Abstract# PO-A13-0248.
66. Ledermann M M, Georges D et al. Procysteine inhibits the expression of the human immunodeficiency virus and expression of the interleukin 2 receptor alpha chain. J Acquir Immun Defici Syndr Hum Retrovirol 1995; 8: 107-115.
67. Kalayjian R C, Skowron G et al. A phase I/II trial of intravenous procysteine in asymptomatic HIV infected patients. J Acquir Immun Defici Syndr 1994; 7: 369-374.
68. Dean S W. Some aspects of glutathione metabolism in ataxia telangiectasia fibroblasts. Int J Radiat Biol Rel Stud Phys Chem Med 1987; 52: 43-48.
69. Meredith M J, Dodson M L. Impaired glutathione biosynthesis in cultured human ataxia telangiectasia cells. Cancer Res 1987; 47: 4576-4581.
70. Grumont R J, Gerondakis S. The subunit composition of NF-kappa B complexes changes during B cell development. Cell Growth Differ 1994; 5: 1321-1331.
71. Feuillard J, Korner M et al. Visualization of the endogenous NF-kappa B p50 subunit in the nucleus of follicular dendritic cells in germinal centers. J Immunol 1994; 152: 12-21.
72. Liou H C, Sha W C et al. Sequential induction of NF-kappa B Rel family proteins during B cell terminal differentiation. Mol Cell Biol 1994; 14: 5349-5359.
73. Sokoloski J A, Narayanan R et al. Role of NF-kappa B in the differentiation and CD11b expression of HL-60 promyelocytic leukemia cells [meeting abstract]. Proc Ann Meet Am Assoc Cancer Res 1994; 35: A3367.
74. Sokoloski J A, Hodnick W F et al. Induction of the differentiation of HL-60 leukemia cells by Vitamin E and other anti-oxidants in combination with Vitamin D3 [meeting abstract]. Proc Ann Meet Am Assoc Cancer Res 1995; 36: A2073.
75. Sokoloski J A, Sartorelli A C et al. Antisense oligonucleotides to the p65 subunit of NF-kappa B block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes. Blood 1993; 82: 625-632.
76. Higuchi M, Singh S et al. Protease inhibitors differentially regulate tumor necrosis alpha induced apoptosis, nuclear factor kappa B activation, cytotoxicity, and differentiation. Blood 1995; 86: 2248-2256.
77. Chen C C, Rosenbloom C L et al. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I-kappa B alpha degradation. J Immunol 1995; 155: 3538-3545.
78. Traenckner E B, Wilk S et al. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I-kappa B alpha that is still bound to NF-kappa B. EMBO J 1994; 13: 5433-5441.
79. Machleidt T, Wiegmann K et al. Sphingomyelinase activates proteolytic I-kappa B alpha degradation in a cell free system. J Biol Chem 1994; 269: 13760-13765.
80. Higuchi M, Singh S et al. Protease inhibitors differentially regulate tumor necrosis factor induced apoptosis, nuclear factor kappa B activation, cytotoxicity, and differentiation. Blood 1995; 86: 2248-2256.
81. Henkel T, Machleidt T et al. Rapid proteolysis of I-kappa alpha is necessary for activation of transcription factor NF kappa B. Nature 1993; 365: 182-185.
82. Menon S D, Guy G R et al. Involvement of a putative protein tyrosine phosphatase and I-kappa B alpha serines phosphorylation in nuclear factor kappa B activation by tumor necrosis factor. J Biol Chem 1995; 270: 18881-18887.
83. Fekade D, Knox K et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 1996; 335: 311-315.
84. Fisher C J, Agosti J M et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334: 1697-1702.
85. Fisher C J, Agosti J M. Tumor necrosis factor receptor: Fc fusion protein in septic shock [letter]. N Engl J Med 1996; 335: 1607-1609.
86. Auphan N, DiDonato J A et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I-kappa B synthesis. Science 1995; 270: 286-290.
87. Scheinman R I, Cogswell P C et al. Role of transcriptional activation of I-kappa alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-286.
88. Hass R, Brach M et al. Inhibition of EGR-1 and NF-kappa B gene expression by dexamethasone during phorbol ester-induced human monocytic differentiation. Biochem Pharmacol 1992; 44: 1569-1576.